First-Line Aumolertinib in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Retrospective...

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Third-generation tyrosine kinase inhibitors (TKIs) are crucial for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations.
• Limited data exists on the efficacy and safety of aumolertinib in this patient population.

Purpose of the Study:

• To evaluate the efficacy and safety of aumolertinib as a first-line therapy for patients with EGFR-mutant aNSCLC.
• To determine progression-free survival (PFS) and overall survival (OS) as primary and secondary endpoints, respectively.

Main Methods:

• Retrospective analysis of clinical records from 47 patients treated with aumolertinib from April 2020 to December 2021.
• Progression-free survival (PFS) and overall survival (OS) were primary and secondary endpoints.
• Adverse events (AEs) were assessed using Common Terminology Criteria for Adverse Events (CTCAE v5.0).

Main Results:

• Median PFS was 22.2 months and median OS was 39.7 months.
• Patients with EGFR exon 19 deletion (19del) had a significantly longer mPFS (28.4 months) compared to L858R mutation (15.2 months, p=0.036).
• Common AEs included rashes (17.0%) and skin issues; Grade 3+ AEs occurred in 4.2% of patients.

Conclusions:

• Aumolertinib shows considerable safety and efficacy for first-line treatment of EGFR-mutant NSCLC.
• The drug offers a promising therapeutic option for patients with advanced non-small cell lung cancer harboring EGFR mutations.